Search results
Biotechs Zero in on New Pancreatic Therapies as Global Pancreatic Cancer Market Expected Reach to...
Morningstar· 1 day agopancreatic cancer market encompasses the pharmaceutical and healthcare sectors dedicated to addressing the prevention, diagnosis, and treatment of
For most, pancreatic cancer is a deadly diagnosis. How one Fort Worth man beat the odds
Fort Worth Star-Telegram McClatchy via AOL· 5 days agoPancreatic cancer has one of the lowest five-year survival rates of any major tumor type,” said Dr....
Verastem (VSTM) Up on Upbeat Early Pancreatic Cancer Study Data
Zacks via Yahoo Finance· 1 day agoVerastem (VSTM) gains 57% post-market on achieving a confirmed partial response in 83% of first-line...
BioLineRx reports positive pancreatic cancer trial results By Investing.com
Investing.com· 1 day ago(NASDAQ: BLRX), a biopharmaceutical company, announced encouraging results from the pilot phase of...
Liposomal Irinotecan for Pancreatic Cancer: Is It Worth It?
Medscape· 5 days agoIn February, the US Food and Drug Administration approved irinotecan liposome (Onivyde) as part of a...
...Clinical Trial Evaluating Motixafortide in First-Line Pancreatic Cancer (PDAC) at American...
FOX 23 News Albany· 1 day agoThe CheMo4METPANC trial is evaluating the company's CXCR4 inhibitor motixafortide, the PD-1...
Oncolytics Biotech® ASCO Abstracts Highlight Pelareorep's Potential in Pancreatic Cancer and...
FOX 23 News Albany· 1 day agoOne is a trial-in-progress abstract discussing cohort 5 of the GOBLET study, which will evaluate the combination of pelareorep and modified FOLFIRINOX (mFOLFIRINOX) with and without atezolizumab ...
Bob Nunnally reveals to NBC4 viewers what type of cancer he had
WCMH via Yahoo News· 1 day agoCOLUMBUS, Ohio (WCMH) — Bob Nunnally knows the difference between himself and the superhero...
Exercise, therapy and diet can all improve life during cancer treatment and boost survival
Medical Xpress· 3 days agoOn the positive side, medical treatments for cancer are advancing very rapidly. Survival rates are...
Alligator Bioscience To Present Positive Phase 2 Mitazalimab Data in Pancreatic Cancer at 2024 ASCO...
Morningstar· 2 days agoOPTIMIZE-1 study results showed confirmed ORR of 40.4%, unconfirmed ORR of 50.9% and DCR of 79% in 57 evaluable patients with chemotherapy-naïve mPDACThe encouraging duration of response (median ...